The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary excretion, diminishing their bioavailability.
The extent of hepatic or first-pass metabolism is quantified as the liver extraction ratio (ER), which is the fraction of the drug removed during its first pass through the liver. It is dictated by hepatic blood clearance rates and circulatory dynamics. Drugs such as theophylline have low extraction ratios and undergo minimal pre-systemic elimination. As a result, such drugs are completely absorbed post-oral administration. In contrast, drugs with high ER, such as verapamil, propranolol, and nitroglycerin, are extensively metabolized pre-systemically. This leads to poor bioavailability and higher dose requirements to achieve desired therapeutic effect.
Alternative administration pathways, such as sublingual or transdermal, are employed to subvert this pre-systemic elimination. For example, 90% of oral nitroglycerin is metabolized pre-systemically. To improve its bioavailability, it is often administered sublingually, which bypasses the pre-systemic metabolism and preserves its potency and therapeutic efficacy.
Most oral drugs are absorbed from the intestines into the hepatic portal vein, passing through the liver before entering the systemic circulation. This leads to pre-systemic elimination, also known as the first-pass effect.
Soon after entering the liver, they are metabolized or excreted into the bile, decreasing their bioavailability or the accessible drug fraction in circulation.
The amount of the drug excreted from the liver is called the liver extraction ratio or ER, measured by drug concentration in the blood entering and exiting the liver.
Notably, ER depends on changes in the hepatic blood clearance and flow, altering the drug's bioavailability.
Drugs with a high extraction ratio undergo extensive pre-systemic metabolism, leading to poor oral bioavailability. So, higher doses are required to achieve an adequate therapeutic response.
Additionally, alternative routes bypass pre-systemic elimination and deliver directly to the systemic circulation.
For instance, upon oral ingestion, 90% of nitroglycerin undergoes pre-systemic elimination. So nitroglycerin is often given sublingually to bypass pre-systemic metabolism.
繁體中文
